ConductScience.org, home
Papers
API referenceFor AI assistants

Paper · 41084837

Dabogratinib (TYRA-300), an FGFR3 Isoform-Selective Inhibitor: Preclinical and Initial Clinical Evidence of Antitumor Activity.

Starrett JH and 14 others. Mol Cancer Ther, 2026. Cited by 0 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Download JSON
Cite this record

ConductScience Library. Dabogratinib (TYRA-300), an FGFR3 Isoform-Selective Inhibitor: Preclinical and Initial Clinical Evidence of Antitumor Activity. Papers, record 41084837. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41084837

On this page

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Dabogratinib (TYRA-300), an FGFR3 Isoform-Selective Inhibitor: Preclinical and Initial Clinical Evidence of Antitumor Activity.
PubMed
Journal
Mol Cancer Ther
PubMed
Year
2026
PubMed
Publication types
Case Reports, Journal Article
PubMed
Citations, by iCite
0
iCite
Revised in PubMed
2026-09-11
PubMed

Authors15

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Starrett JHJacqueline Hhttps://orcid.org/0000-0002-4970-7491
2Allen ELEric Lhttps://orcid.org/0009-0003-6369-5989
3Neal MMelissahttps://orcid.org/0009-0003-8323-547X
4Iyer SSamhitahttps://orcid.org/0000-0002-9514-5477
5Ye QQinghttps://orcid.org/0009-0000-1947-1759
6Hudkins RLRobert Lhttps://orcid.org/0009-0008-8250-7679
7Degaonkar VVirajhttps://orcid.org/0009-0009-4992-7599
8Lihou CChristinehttps://orcid.org/0000-0002-2424-5948
9Swanson RVRonald Vhttps://orcid.org/0000-0002-6486-2676
10Boni VValentinahttps://orcid.org/0000-0002-8675-0018

1 to 10 of 15Source PubMed

See all 15 authors

Topics16

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Antineoplastic AgentsMajor topic
Protein Kinase InhibitorsMajor topic
Receptor, Fibroblast Growth Factor, Type 3Major topic
Urinary Bladder NeoplasmsMajor topic
Animals
Female
Humans
Male
Mice
Middle Aged
Cell Line, Tumor
Mutation
Protein Isoforms
Xenograft Model Antitumor Assays
Clinical Trials, Phase II as Topic
Clinical Trials, Phase I as Topic

Source PubMed

Grants0

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

None in this release.

Trials0

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

None in this release.

Comments and corrections0

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

None in this release.

References16

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
129,848,605Efficacy of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Inhibitor, in Patients with Previously Treated Advanced Urothelial Carcinoma with FGFR3 Alterations.Cancer Discov2018https://conductscience.org/library/papers/29848605PubMed
211,395,371Frequent FGFR3 mutations in papillary non-invasive bladder (pTa) tumors.Am J Pathol2001https://conductscience.org/library/papers/11395371PubMed
331,340,094Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma.N Engl J Med2019https://conductscience.org/library/papers/31340094PubMed
428,601,352Comprehensive Genomic Characterization of Upper Tract Urothelial Carcinoma.Eur Urol2017https://conductscience.org/library/papers/28601352PubMed
539,258,897Discovery of TYRA-300: First Oral Selective FGFR3 Inhibitor for the Treatment of Urothelial Cancers and Achondroplasia.J Med Chem2024https://conductscience.org/library/papers/39258897PubMed
626,278,805Genomic Characterization of Upper Tract Urothelial Carcinoma.Eur Urol2015https://conductscience.org/library/papers/26278805PubMed
710,471,491Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas.Nat Genet1999https://conductscience.org/library/papers/10471491PubMed
837,377,403Resistance to Selective FGFR Inhibitors in FGFR-Driven Urothelial Cancer.Cancer Discov2023https://conductscience.org/library/papers/37377403PubMed
938,838,500An open-label study of pemigatinib in cholangiocarcinoma: final results from FIGHT-202.ESMO Open2024https://conductscience.org/library/papers/38838500PubMed
1026,373,574The FGFR Landscape in Cancer: Analysis of 4,853 Tumors by Next-Generation Sequencing.Clin Cancer Res2016https://conductscience.org/library/papers/26373574PubMed

1 to 10 of 16

See all 16 references

Cited by1

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 0 citations.

PMIDTitleJournalYearIn Papers
42,650,460From FGFR3 Hyperactivation to Disease-Modifying Therapy in Pediatric Achondroplasia: Molecular Mechanisms, Clinical Evidence, and Emerging Treatments.Children (Basel)2026https://conductscience.org/library/papers/42650460

Source PubMed

Genes1

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn Genes
FGFR32,261PubTator's text mininghttps://conductscience.org/library/genes/2261

Source NCBI Gene

Drugs0

The drugs whose trials, in the Pipelines release, list the paper.

None in this release.

Data0

The data bank entries PubMed's record names. Trial numbers are under Trials.

None in this release.

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/41084837

GET https://conductscience.org/api/papers/v1/41084837/authors

API referenceFor AI assistants